The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is a huge mover today! About 745,584 shares traded hands. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has declined 33.01% since April 13, 2016 and is downtrending. It has underperformed by 36.93% the S&P500.
The move comes after 5 months negative chart setup for the $375.70M company. It was reported on Nov, 15 by Barchart.com. We have $3.87 PT which if reached, will make NASDAQ:SPPI worth $45.08 million less.
According to Zacks Investment Research, “Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum’s expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company’s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.”
Insitutional Activity: The institutional sentiment increased to 3.84 in 2016 Q2. Its up 2.68, from 1.16 in 2016Q1. The ratio improved, as 7 funds sold all Spectrum Pharmaceuticals, Inc. shares owned while 18 reduced positions. 34 funds bought stakes while 62 increased positions. They now own 106.93 million shares or 131.39% more from 46.21 million shares in 2016Q1.
Blackrock Institutional Tru Comm Na accumulated 1.89M shares or 0% of the stock. The Maryland-based Price T Rowe Associate Md has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Denver Advsrs Ltd Llc, a Colorado-based fund reported 16,785 shares. Diam last reported 139,797 shares in the company. Teacher Retirement System Of Texas holds 0% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 9,513 shares. Jpmorgan Chase And Comm accumulated 66 shares or 0% of the stock. Macquarie last reported 0.02% of its portfolio in the stock. Campbell & Communications Investment Adviser accumulated 0.78% or 23,450 shares. Principal has 439,980 shares for 0% of their US portfolio. Grp One Trading Limited Partnership accumulated 10,737 shares or 0% of the stock. Invesco owns 667,368 shares or 0% of their US portfolio. Goldman Sachs Gru Inc holds 0% or 1.57 million shares in its portfolio. The Kentucky-based Teachers Retirement Of The State Of Kentucky has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Morgan Stanley accumulated 0% or 298,150 shares. Art Advsrs Ltd Limited Liability Company holds 0.07% or 205,678 shares in its portfolio.
Another recent and important Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news was published by Businesswire.com which published an article titled: “IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action …” on November 08, 2016.
SPPI Company Profile
Spectrum Pharmaceuticals, Inc., incorporated on November, 18, 2002, is a biotechnology company. The Firm operates through developing and commercializing oncology and hematology drug products segment. The Firm has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. The Company’s commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. The Company’s other products include SPI-2012, POZIOTINIB and EOQUIN.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.